Linking in vitro and ex vivo CB1 activity with serum concentrations and clinical features in 5F-MDMB-PICA users to better understand SCRAs and their metabolites-Reference-Cited by-同舟云学术

Linking in vitro and ex vivo CB1 activity with serum concentrations and clinical features in 5F-MDMB-PICA users to better understand SCRAs and their metabolites

Published:2022-08-12 Issue:11 Volume:96 Page:2935-2945
ISSN:0340-5761
Container-title:Archives of Toxicology
language:en
Short-container-title:Arch Toxicol

Author:

Janssens Liesl K.^ORCID,Hudson Simon^ORCID,Wood David M.^ORCID,Wolfe Caitlin^ORCID,Dargan Paul I.^ORCID,Stove Christophe P.^ORCID

Funder

Bijzonder Onderzoeksfonds UGent

Publisher

Springer Science and Business Media LLC

Subject

Health, Toxicology and Mutagenesis,Toxicology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00204-022-03355-6.pdf

Reference32 articles.

1. Adams AJ, Banister SD, Irizarry L et al (2017) “Zombie” outbreak caused by the Synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med 376:235–242. https://doi.org/10.1056/NEJMoa1610300

2. Apirakkan O, Hudson S, Couchman L et al (2021) The first reported case of a synthetic cannabinoid ethyl ester detected in a postmortem blood toxicological analysis. J Anal Toxicol 44:1052–1056. https://doi.org/10.1093/jat/bkaa030

3. Banister SD, Connor M (2018) The chemistry and pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: evolution. In: Maurer HH, Brandt SD (eds) New Psychoactive Substances. Springer International Publishing, Cham, pp 191–226

4. Banister SD, Longworth M, Kevin R et al (2016) Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci 7:1241–1254. https://doi.org/10.1021/acschemneuro.6b00137

5. Cabanlong CV, Russell LN, Fantegrossi WE, Prather PL (2022) Metabolites of synthetic cannabinoid 5F-MDMB-PINACA retain affinity, act as high efficacy agonists and exhibit atypical pharmacodynamic properties at CB1 receptors. Toxicol Sci 187(1):175–185. https://doi.org/10.1093/toxsci/kfac024

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review on activity-based detection of doping substances and growth promotors in biological matrices: do bioassays deserve a place in control programs?;Analytica Chimica Acta;2024-09

2. Interpreting mono- and poly-SCRA intoxications from an activity-based point of view: JWH-018 equivalents in serum as a comparative measure;Archives of Toxicology;2024-08-08

3. Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor;ACS Chemical Neuroscience;2023-10-17

4. Focusing on the 5F-MDMB-PICA, 4F-MDMB-BICA synthetic cannabinoids and their primary metabolites in analytical and pharmacological aspects;Toxicology and Applied Pharmacology;2023-07

5. A subtle structural modification of a synthetic cannabinoid receptor agonist drastically increases its efficacy at the CB1 receptor;2023-06-12